It is now more than 10 years since one of us (J.J.) introduced a classification for CDG (CDG Ia etc., CDG IIa etc.) essentially on the basis of the serum transferrin pattern obtained by isoelectrofocusing (Jaeken et al 1994) . A nomenclature system that essentially (sub)classified the different types of CDG alphabetically was proposed by the participants of the First International workshop on CDG and related disorders, in Leuven in 1999, and widely announced (Aebi et al 1999; Matthijs 2000; Participants 2000) . We think that time has come to reconsider this matter. More specifically, it is our strong feeling that the current classification should be discontinued for a number of reasons.
1. The number of CDG has increased tremendously.
In the 28 years that have elapsed since the first description of patients, some 40 types of CDG (including protein and lipid glycosylation defects) have been discovered (Jaeken and Matthijs 2007; Freeze 2007 (Kranz et al 2007) , the lipid glycosylation disorders (Simpson et al 2004) and so on?
Our suggestion is to keep (of course) Congenital Disorders of Glycosylation (CDG) as an umbrella name for all protein glycosylation disorders and to extend it to the lipid glycosylation disorders. To indicate the specific disorder, we propose to make obligatory the use of the gene name. But in parallel, the name of the protein (enzyme, transporter, chaperone, ...) may be used (abbreviated or not; this may be a Ftrivial_ name: e.g. CDG due to mannosyltransferase VIII deficiency instead of dolichol-P-Man:Man 7 GlcNAc 2 -PP-dolichol mannosyltransferase deficiency). In a transition period the Fold_ nomenclature can be included in brackets as that nomenclature is gradually replaced (see the Tables 1-4). One is free to add the abbreviated designation CDG in brackets after the gene name: e.g. PMM2 deficiency (CDG).
As long as the primary (genetic) defect is unknown for a specific type, we will continue to call the disease CDG-x; hence, this group constitutes a series of cases and patients Fto be solved_.
We look forward to receiving comments on this proposal. Phosphomannose isomerase 602579 ALG6 (CDG-Ic) Dol-P-Glc:Man 9 -GlcNAc 2 -P-P-Dol glucosyltransferase (glucosyltransferase 1) 603147 NOT56L (CDG-Id) Dol-P-Man:Man 5 -GlcNAc 2 -P-P-Dol mannosyltransferase (mannosyltransferase 6) 601110 ALG 12 (CDG-Ig) Dol-P-Man:Man 7 -GlcNAc 2 -P-P-Dol mannosyltransferase (mannosyltransferase 8) 607143 ALG 8 (CDG-Ih) Dol-P-Glc:Glc 1 -Man 9 -GlcNAc 2 -P-P-Dol glucosyltransferase (glucosyltransferase 2) 608104 ALG2 (CDG-Ii) GDP-Man:Man 1 -GlcNAc 2 -P-P-Dol mannosyltransferase (mannosyltransferase 2) 607906 DPAGT1 (CDG-Ij) UDP-GlcNAc:Dol-P-GlcNAc-P transferase 608093 HMT1 (CDG-Ik) GDP-Man:GlcNAc 2 -P-P-Dol mannosyltransferase (mannosyltransferase 1) 608540 DIBD1 (CDG-Il) Dol-P-Man:Man 6 -and Man 8 -GlcNA 2 -P-P-Dol mannosyltransferase (mannosyltransferase 7-9) Proposed nomenclature for CDG (nomenclature to be superseded is included in italics within brackets) 
